Skip to content

The value of hepatobiliary contrast agents quantitative parameters in predicting postoperative liver failure and hepatocellular carcinoma subtypes in HCC patients

The value of hepatobiliary contrast agents–enhanced biliary imaging in predicting postoperative liver failure in HCC patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300072395
Enrollment
Unknown
Registered
2023-06-12
Start date
2021-10-10
Completion date
Unknown
Last updated
2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cancer

Interventions

Gold Standard:Pathological results (HE staining, immunohistochemical staining)
Index test:MRI imaging features (quantitative parameters from gadobenate dimeglumine-enhanced MRI)

Sponsors

Shandong Provincial Hospital Affiliated to Shandong First Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
28 Years to 82 Years

Inclusion criteria

Inclusion criteria: (a) Complete MRI images before surgery; (b) Available results of pathological sections (HE staining and immunohistochemical staining). (c) Complete clinical data before surgery.

Exclusion criteria

Exclusion criteria: (1) the existence of additional disorders that may affect the patient's survival ; (2) insufficient data from preoperative gadobenate dimeglumine-enhanced MRI of the hepatobiliary phase ; (3) transcatheter arterial chemoembolization, microwave ablation or radiofrequency ablation were performed prior to surgical resection ; (4) postoperative patients with other malignancies and (or) distant organ metastases ; (5) image quality problems or lack of biochemical parameter data; (6) histologically confirmed multiple HCC

Design outcomes

Primary

MeasureTime frame
The lesion-to-liver contrast enhancement ratio(LLCER);The relative enhancement ratio of the biliary system(REB);

Secondary

MeasureTime frame
Positive predictive value;Negative predictive value ;Sensitivity ;Specificity ;lesion-to-liver contrast (LLC);Area under the curve;

Countries

China

Contacts

Public ContactZhao Xinya

Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First

zhaoxinya2000@126.com+86 15 168 888 7805

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026